These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 7888232

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
    Johnson VA, Merrill DP, Videler JA, Chou TC, Byington RE, Eron JJ, D'Aquila RT, Hirsch MS.
    J Infect Dis; 1991 Oct; 164(4):646-55. PubMed ID: 1716649
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds.
    Wondimu Z, Sönnerborg A, Ayehunie S, Britton S, Strannegård O.
    Antiviral Res; 1992 Oct 01; 19(4):353-9. PubMed ID: 1281393
    [Abstract] [Full Text] [Related]

  • 6. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
    Periclou AP, Nandy P, Avramis VI.
    In Vivo; 2000 Oct 01; 14(3):377-88. PubMed ID: 10904870
    [Abstract] [Full Text] [Related]

  • 7. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
    St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD, Larder BA.
    Science; 1991 Sep 27; 253(5027):1557-9. PubMed ID: 1716788
    [Abstract] [Full Text] [Related]

  • 8. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol.
    Heredia A, Davis C, Redfield R.
    J Acquir Immune Defic Syndr; 2000 Nov 01; 25(3):246-55. PubMed ID: 11115955
    [Abstract] [Full Text] [Related]

  • 9. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine.
    Kong XB, Zhu QY, Ruprecht RM, Watanabe KA, Zeidler JM, Gold JW, Polsky B, Armstrong D, Chou TC.
    Antimicrob Agents Chemother; 1991 Oct 01; 35(10):2003-11. PubMed ID: 1722077
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.
    Kim EY, Vrang L, Oberg B, Merigan TC.
    AIDS Res Hum Retroviruses; 2001 Mar 20; 17(5):401-7. PubMed ID: 11282008
    [Abstract] [Full Text] [Related]

  • 12. Decreased anti-human immunodeficiency virus type-1 activities of 2',3'-dideoxynucleoside analogs in MOLT-4 cell sublines resistant to 2',3'-dideoxynucleoside analogs.
    Cinatl J, Cinatl J, Weber B, Rabenau H, Weissflog A, Mainke M, Kornhuber B, Doerr HW.
    Acta Virol; 1993 Oct 20; 37(5):360-8. PubMed ID: 8184788
    [Abstract] [Full Text] [Related]

  • 13. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.
    Shirasaka T, Yarchoan R, O'Brien MC, Husson RN, Anderson BD, Kojima E, Shimada T, Broder S, Mitsuya H.
    Proc Natl Acad Sci U S A; 1993 Jan 15; 90(2):562-6. PubMed ID: 8380641
    [Abstract] [Full Text] [Related]

  • 14. [What is known about the cellular and molecular pharmacodynamics of nucleosides?].
    Sommadossi JP.
    Pathol Biol (Paris); 1993 Oct 15; 41(8 Pt 2):781-7. PubMed ID: 8309721
    [Abstract] [Full Text] [Related]

  • 15. Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay.
    McLeod GX, McGrath JM, Ladd EA, Hammer SM.
    Antimicrob Agents Chemother; 1992 May 15; 36(5):920-5. PubMed ID: 1510414
    [Abstract] [Full Text] [Related]

  • 16. Differential antiviral activities and intracellular metabolism of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in human cells.
    Mukherji E, Au JL, Mathes LE.
    Antimicrob Agents Chemother; 1994 Jul 15; 38(7):1573-9. PubMed ID: 7526781
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir.
    Hossain MM, Coull JJ, Drusano GL, Margolis DM.
    Antiviral Res; 2002 Jul 15; 55(1):41-52. PubMed ID: 12076750
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the combination effect of different antiviral compounds against HIV in vitro.
    Sørensen AM, Nielsen C, Mathiesen LR, Nielsen JO, Hansen JE.
    Scand J Infect Dis; 1993 Jul 15; 25(3):365-71. PubMed ID: 7689746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.